文献速递肝病消化道肿瘤与早癌消化内镜

基于超声可视化评分C触发简化MRI的NAFLD肝硬化肝细胞癌监测的成本效果分析

Cost-Effectiveness Analysis of Hepatocellular Carcinoma Surveillance in Nonalcoholic Fatty Liver Disease Cirrhosis Using US Visualization Score C-Triggered Abbreviated MRI.
PubMed 文献 · Am J Gastroenterol · 2023-12-26

该研究构建Markov模型模拟美国代偿期NAFLD肝硬化成人,比较超声联合可视化评分(评分C且超声阴性者行简化MRI)、单用超声及不监测三种策略。结果显示超声联合可视化评分最具成本效果,相对不监测的ICER为59005美元/质量调整生命年;单用超声相对该策略的ICER为822500美元。即使超声联合甲胎蛋白,该策略仍具成本效果(ICER 62799美元)。

要点

  • 超声联合可视化评分策略最具成本效果,ICER为59005美元/质量调整生命年。
  • 单用超声相对联合策略的ICER为822500美元,远超支付意愿阈值。
  • 超声联合甲胎蛋白时联合策略仍具成本效果,ICER为62799美元。

核心结论

  • 在NAFLD肝硬化患者中,基于超声可视化评分、对评分C者行简化MRI的HCC监测策略似乎是最具成本效果的策略。

研究设计与样本

  • 构建Markov模型模拟美国代偿期NAFLD肝硬化成人接受HCC监测。
  • 比较超声联合可视化评分、单用超声及不监测三种策略。
  • 对可视化评分C且超声阴性者模拟简化MRI,评分A/B者仅行超声。
  • 支付意愿阈值为每质量调整生命年100000美元。

主要发现

  • 超声联合可视化评分相对不监测的ICER为59005美元。
  • 单用超声相对超声联合可视化评分的ICER为822500美元。
  • 敏感性分析中,超声联合可视化评分在多个参数下仍为首选策略。
  • 超声联合甲胎蛋白时,超声联合可视化评分相对不监测的ICER为62799美元。

关键数值与推荐

  • 超声联合可视化评分相对不监测的ICER为59005美元,低于100000美元/质量调整生命年的支付意愿阈值。
  • 单用超声相对超声联合可视化评分的ICER为822500美元。
  • 超声联合可视化评分联合甲胎蛋白时相对不监测的ICER为62799美元。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Ultrasound (US) is associated with severe visualization limitations (US Liver Imaging Reporting and Data System visualization score C) in one-third of patients with nonalcoholic fatty liver disease (NAFLD) cirrhosis undergoing hepatocellular carcinoma (HCC) screening. Data suggest abbreviated MRI (aMRI) may improve HCC screening efficacy. This study analyzed the cost-effectiveness of HCC screening strategies, including an US visualization score-based approach with aMRI, in patients with NAFLD cirrhosis. METHODS: We constructed a Markov model simulating adults with compensated NAFLD cirrhosis in the United States undergoing HCC screening, comparing strategies of US plus visualization score, US alone, or no surveillance. We modeled aMRI in patients with visualization score C and negative US, while patients with scores A/B did US alone. We performed a sensitivity analysis comparing US plus visualization score with US plus alpha fetoprotein or no surveillance. The primary outcome was the incremental cost-effectiveness ratio (ICER), with a willingness-to-pay threshold of $100,000 per quality-adjusted life-year. Sensitivity analyses were performed for all variables. RESULTS: US plus visualization score was the most cost-effective strategy, with an ICER of $59,005 relative to no surveillance. The ICER for US alone to US plus visualization score was $822,500. On sensitivity analysis, screening using US plus visualization score remained preferred across several parameters. Even with alpha fetoprotein added to US, the US plus visualization score strategy remained cost-effective, with an ICER of $62,799 compared with no surveillance. DISCUSSION: HCC surveillance using US visualization score-based approach, using aMRI for visualization score C, seems to be the most cost-effective strategy in patients with NAFLD cirrhosis.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Mulgaonkar A, Huang DQ, Siddiqi H, et al. Cost-Effectiveness Analysis of Hepatocellular Carcinoma Surveillance in Nonalcoholic Fatty Liver Disease Cirrhosis Using US Visualization Score C-Triggered Abbreviated MRI. Am J Gastroenterol. 2023. PMID: 38146873. doi:10.14309/ajg.0000000000002636

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。